{
    "clinical_study": {
        "@rank": "11477", 
        "arm_group": [
            {
                "arm_group_label": "ABH001", 
                "arm_group_type": "Other", 
                "description": "ABH001 application plus wound care dressings."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Control wound treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of ABH001 in the treatment\n      of patients with epidermolysis bullosa who have wounds that are not healing.\n\n      It is hypothesized that ABH001 may initiate and continue wound healing in patients with\n      epidermolysis bullosa."
        }, 
        "brief_title": "A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Epidermolysis Bullosa", 
        "condition_browse": {
            "mesh_term": "Epidermolysis Bullosa"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject or legal guardian must have read, understood and signed an Institutional\n             Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and\n             must be able to and willing to follow study procedures and instructions\n\n          2. Male and female subjects.\n\n          3. Stable nutritional status.\n\n          4. Subjects with a confirmed diagnosis of generalized Epidermolysis Bullosa (EB)\n\n          5. Cutaneous wounds meeting the following criteria:\n\n               1. Anatomical location: arms, legs, thorax, or back above the waistline and below\n                  the neck.\n\n               2. Documented age (duration) of the wound(s).\n\n               3. One or more wounds capable of potentially meeting the following wound selection\n                  criteria at the end of the observation period:\n\n             i. Two clinically non-infected cutaneous wounds with no clinically meaningful change\n             in wound size during the observation period.\n\n             ii. Two matched wounds.\n\n          6. Negative urine pregnancy test for women of child-bearing potential.\n\n          7. Female subjects of childbearing potential and male subjects of procreative capacity\n             must agree to use an effective method of contraception.\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing women.\n\n          2. Diagnosis of non-genetic generalized EB.\n\n          3. Localized, active clinical infection of study wounds.\n\n          4. Diseases or conditions that could interfere with the assessment of safety and\n             efficacy of the study treatment and compliance of the subject with study\n             visits/procedures.\n\n          5. Known allergy to bovine products.\n\n          6. Known allergy to silver products.\n\n          7. Systemic infection at the time of enrolment in the study.\n\n          8. Currently receiving or have received oral steroid therapy within the previous 4\n             weeks.\n\n          9. Taking, or have participated in other clinical studies involving gene therapy, stem\n             cell therapy, recombinant DNA/protein therapy.\n\n         10. Received ABH001, or other biologic or cell therapy for the treatment of EB in the\n             study wound sites within the previous 3 months.\n\n         11. Hypersensitivity to any of the therapeutic agents.\n\n         12. History of malignant skin disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749306", 
            "org_study_id": "EB01-ABH001", 
            "secondary_id": "2012-001815-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "ABH001", 
                "description": "ABH001 applications topically every 4 weeks (\u00b11 week) with protocol-specified dressings until wound healed or up to 44 weeks", 
                "intervention_name": "ABH001", 
                "intervention_type": "Biological", 
                "other_name": "Dermagraft, Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide) (PGLLA) Scaffold"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Control wound care with protocol-specified dressings every 4 weeks (\u00b11 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks", 
                "intervention_name": "Control wound treatment", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "epidermolysis bullosa, chronic wound, wound healing, dermal repair, fibroblasts, Dermagraft", 
        "lastchanged_date": "November 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Phoenix Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Redwood City", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Lucile Packard Children's Hospital at Stanford University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Denver Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Ann & Robert H. Lurie Children's Hospital of Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "Virginia Clinical Research, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria"
                    }, 
                    "name": "Landeskrankenhaus Salzburg-Universit\u00e4tsklinikum der Paracelsus Medizinischen Privatuniversit\u00e4t"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Toronto Regional Wound Healing Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "University of Montreal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Ile-De France"
                    }, 
                    "name": "H\u00f4pital Necker-Enfants Malades"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg"
                    }, 
                    "name": "University of Freiburg (Studiensekretariat Hautklinik Universit\u00e4tsklinikum Freiburg - Hautklinik)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "state": "Mazowieckie"
                    }, 
                    "name": "Warszawki Uniwersytet Medyczny Katedra I Klinika Dermatologiczna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal"
                    }, 
                    "name": "Hospital CUF Descobertas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Canada", 
                "France", 
                "Germany", 
                "Poland", 
                "Portugal", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa", 
        "overall_official": {
            "affiliation": "H&E Enterprises", 
            "last_name": "Alan Arbuckle, MD, FAAD, FAAP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Reduction in wound surface area", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in wound pain and wound itch", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Patient global impression of change (PGIC)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Clinician global impression of change (CGIC)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Proportion of subjects achieving reduction in wound surface area", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Time to reduction of wound surface area and duration of reduction", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Durability of wound healing", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Incidence, relatedness and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 Weeks"
            }
        ], 
        "source": "Shire Regenerative Medicine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire Regenerative Medicine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}